Clinical Trial Update: Sutent Maintenance After Response to Taxotere [Phase 2]

View source ↗

Summary

Phase 2 trial update of maintenance sunitinib (Sutent) after response to docetaxel (Taxotere) in hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sutent (sunitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Alberta Health services | Conditions: Prostate Cancer, Hormone Refractory | Phase 2 | Status: UNKNOWN